<p>药明康德（NYSE:RDY - 获取免费报告）在周四发布给客户和投资者的研究报告中，被汇丰的股票研究分析师从 “持有” 评级上调至 “买入” 评级。该公司目前对该股票的目标价为 16.90 美元。汇丰的目标价意味着该公司当前价格有 14.50% 的潜在上涨空间。</p>
<ul>
<li>Teva Pharmaceuticals 股票：发掘这款仿制药的价值</li>
</ul>
<p>另外，华尔街 Zen 在 5 月 8 日的研究报告中将药明康德的股票评级从 “持有” 上调至 “买入”。</p>
<p><strong>查看我们最新的 RDY 股票分析</strong></p>
<h2>药明康德股价上涨 0.7%</h2>
<ul>
<li>2 只被忽视的股票，盈利超预期但股价下跌</li>
</ul>
<p>周四，RDY 的开盘价为 14.76 美元。该公司的市值为 123.2 亿美元，市盈率为 23.50，贝塔值为 0.33。公司的 50 日简单移动平均线为 13.77 美元，200 日简单移动平均线为 14.02 美元。药明康德的 1 年最低价为 12.26 美元，1 年最高价为 16.89 美元。该公司的债务股本比为 0.02，流动比率为 1.92，速动比率为 1.38。</p>
<p>药明康德（NYSE:RDY - 获取免费报告）最后一次公布季度财报是在 5 月 9 日，周五。该公司报告本季度每股收益为 0.22 美元，超出分析师一致预期的 0.20 美元，超出幅度为 0.02 美元。该公司本季度的收入为 9.9617 亿美元，而一致预期为 837 亿美元。药明康德的股本回报率为 17.87%，净利润率为 17.25%。分析师预计药明康德在当前财政年度将发布 0.8 美元的每股收益。</p>
<h2>药明康德的机构交易</h2>
<ul>
<li>制药公司 GSK：成为更健康的价值股</li>
</ul>
<p>一些机构投资者和对冲基金最近增加或减少了对 RDY 的持股。Costello Asset Management INC 在第一季度购买了药明康德的新股份，价值 26,000 美元。EverSource Wealth Advisors LLC 在第四季度将其在药明康德的持股增加了 423.3%。EverSource Wealth Advisors LLC 现在拥有 1,863 股该公司的股票，价值 29,000 美元，此前在上个季度增持了 1,507 股。Glass Jacobson Investment Advisors llc 在第四季度将其在药明康德的持股增加了 400.0%。Glass Jacobson Investment Advisors llc 现在拥有 2,000 股该公司的股票，价值 32,000 美元，此前在上个季度增持了 1,600 股。POM Investment Strategies LLC 在第四季度将其在药明康德的持股增加了 400.0%。POM Investment Strategies LLC 现在拥有 2,275 股该公司的股票，价值 36,000 美元，此前在此期间增持了 1,820 股。最后，Farther Finance Advisors LLC 在第四季度将其在药明康德的持股增加了 461.0%。Farther Finance Advisors LLC 现在拥有 2,547 股该公司的股票，价值 40,000 美元，此前在此期间增持了 2,093 股。对冲基金和其他机构投资者持有该公司 3.85% 的股份。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德有限公司及其子公司在全球范围内作为一家综合制药公司运营。它通过全球仿制药、制药服务和活性成分（PSAI）及其他部门运营。公司的全球仿制药部门生产和销售处方药和非处方药成品，这些产品以品牌名称或作为具有治疗等效性的仿制成品剂型进行市场营销，同时还参与生物制药业务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>什么是股息之王？</li>
<li>Alphabet 股票分析：接下来会是牛市还是熊市？</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>3 只盈利大、风险平衡的公用事业股票</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>NVIDIA 重夺榜首；FOMO 是其持续上涨的原因</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而药明康德并不在名单上。</p>
<p>虽然药明康德目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

如瑞迪博士

<p>汇丰银行将药明康德（NYSE:RDY）的评级从 “持有” 上调至 “买入”，目标价格设定为 16.90 美元，意味着潜在上涨空间为 14.50%。该股票开盘价为 14.76 美元，市值为 123.2 亿美元。公司在上一季度报告的每股收益为 0.22 美元，超出预期。机构投资者最近显著增加了对公司的持股。药明康德作为一家综合制药公司，专注于仿制药和活性成分</p>

<p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) was upgraded by equities research analysts at HSBC from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Thursday. The firm presently has a $16.90 target price on the stock. HSBC's target price would indicate a potential upside of 14.50% from the company's current price.</p>
<div class="lb-trans"><p>药明康德（NYSE:RDY - 获取免费报告）在周四发布给客户和投资者的研究报告中，被汇丰的股票研究分析师从 “持有” 评级上调至 “买入” 评级。该公司目前对该股票的目标价为 16.90 美元。汇丰的目标价意味着该公司当前价格有 14.50% 的潜在上涨空间。</p>
</div><ul>
<li>Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharmaceuticals 股票：发掘这款仿制药的价值</li>
</ul>
</div><p>Separately, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 8th.</p>
<div class="lb-trans"><p>另外，华尔街 Zen 在 5 月 8 日的研究报告中将药明康德的股票评级从 “持有” 上调至 “买入”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on RDY</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 RDY 股票分析</strong></p>
</div><h2>Dr. Reddy's Laboratories Trading Up 0.7%</h2>
<div class="lb-trans"><h2>药明康德股价上涨 0.7%</h2>
</div><ul>
<li>2 overlooked stocks that crushed earnings but traded lower</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只被忽视的股票，盈利超预期但股价下跌</li>
</ul>
</div><p>RDY opened at $14.76 on Thursday. The firm has a market capitalization of $12.32 billion, a price-to-earnings ratio of 23.50 and a beta of 0.33. The company's 50 day simple moving average is $13.77 and its two-hundred day simple moving average is $14.02. Dr. Reddy's Laboratories has a 1-year low of $12.26 and a 1-year high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.</p>
<div class="lb-trans"><p>周四，RDY 的开盘价为 14.76 美元。该公司的市值为 123.2 亿美元，市盈率为 23.50，贝塔值为 0.33。公司的 50 日简单移动平均线为 13.77 美元，200 日简单移动平均线为 14.02 美元。药明康德的 1 年最低价为 12.26 美元，1 年最高价为 16.89 美元。该公司的债务股本比为 0.02，流动比率为 1.92，速动比率为 1.38。</p>
</div><p>Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million for the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts expect that Dr. Reddy's Laboratories will post 0.8 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NYSE:RDY - 获取免费报告）最后一次公布季度财报是在 5 月 9 日，周五。该公司报告本季度每股收益为 0.22 美元，超出分析师一致预期的 0.20 美元，超出幅度为 0.02 美元。该公司本季度的收入为 9.9617 亿美元，而一致预期为 837 亿美元。药明康德的股本回报率为 17.87%，净利润率为 17.25%。分析师预计药明康德在当前财政年度将发布 0.8 美元的每股收益。</p>
</div><h2>Institutional Trading of Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>药明康德的机构交易</h2>
</div><ul>
<li>Drugmaker GSK: Becoming a Healthier Value Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>制药公司 GSK：成为更健康的价值股</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in RDY. Costello Asset Management INC purchased a new position in shares of Dr. Reddy's Laboratories during the first quarter worth $26,000. EverSource Wealth Advisors LLC lifted its stake in Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after acquiring an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc lifted its stake in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock worth $32,000 after acquiring an additional 1,600 shares in the last quarter. POM Investment Strategies LLC boosted its holdings in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in Dr. Reddy's Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after acquiring an additional 2,093 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对 RDY 的持股。Costello Asset Management INC 在第一季度购买了药明康德的新股份，价值 26,000 美元。EverSource Wealth Advisors LLC 在第四季度将其在药明康德的持股增加了 423.3%。EverSource Wealth Advisors LLC 现在拥有 1,863 股该公司的股票，价值 29,000 美元，此前在上个季度增持了 1,507 股。Glass Jacobson Investment Advisors llc 在第四季度将其在药明康德的持股增加了 400.0%。Glass Jacobson Investment Advisors llc 现在拥有 2,000 股该公司的股票，价值 32,000 美元，此前在上个季度增持了 1,600 股。POM Investment Strategies LLC 在第四季度将其在药明康德的持股增加了 400.0%。POM Investment Strategies LLC 现在拥有 2,275 股该公司的股票，价值 36,000 美元，此前在此期间增持了 1,820 股。最后，Farther Finance Advisors LLC 在第四季度将其在药明康德的持股增加了 461.0%。Farther Finance Advisors LLC 现在拥有 2,547 股该公司的股票，价值 40,000 美元，此前在此期间增持了 2,093 股。对冲基金和其他机构投资者持有该公司 3.85% 的股份。</p>
</div><h2>About Dr. Reddy's Laboratories</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.</p>
<div class="lb-trans"><p>药明康德有限公司及其子公司在全球范围内作为一家综合制药公司运营。它通过全球仿制药、制药服务和活性成分（PSAI）及其他部门运营。公司的全球仿制药部门生产和销售处方药和非处方药成品，这些产品以品牌名称或作为具有治疗等效性的仿制成品剂型进行市场营销，同时还参与生物制药业务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Dr. Reddy's Laboratories</li>
<li>What is a Dividend King?</li>
<li>Alphabet Stock Analysis: What's Next—Bull or Bear Market?</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Utilities Stocks With Big Earnings, Balanced Risk</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>什么是股息之王？</li>
<li>Alphabet 股票分析：接下来会是牛市还是熊市？</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>3 只盈利大、风险平衡的公用事业股票</li>
<li>如何投资科技股以及值得考虑的顶级科技股</li>
<li>NVIDIA 重夺榜首；FOMO 是其持续上涨的原因</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dr. Reddy's Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Dr. Reddy's Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而药明康德并不在名单上。</p>
</div><p>While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

如瑞迪博士实验室（NYSE:RDY）被汇丰银行提升至 “买入” 评级